Comparison of Conventional Chemotherapy, Stealth Liposomes and Temperature-Sensitive Liposomes in a Mathematical Model

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Gasselhuber, Astrid ^a,c   Dreher, Matthew R ^b   Rattay, Frank ^c   Wood, Bradford J ^b   Haemmerich, Dieter ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^d AMRL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; STEALTH LIPOSOME; TEMPERATURE SENSITIVE LIPOSOME; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; EXTRAVASCULAR TRIGGERED RELEASE; INTRAVASCULAR TRIGGERED RELEASE; MATHEMATICAL MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BODY TEMPERATURE; CELL LINE, TUMOR; DOXORUBICIN; INTRACELLULAR SPACE; LIPOSOMES; MICE; MODELS, BIOLOGICAL; TEMPERATURE; TIME FACTORS;

EID: 84867637665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047453     Document Type: Article

References (48)

1. Vora J, Boroujerdi M, (1996) Pharmacokinetic-toxicodynamic relationships of adriamycin in rat: prediction of butylated hydroxyanisole-mediated reduction in anthracycline cardiotoxicity. J Pharm Pharmacol 48: 1264-1269.
2. Doroshow JH (2006) Anthracyclines and Anthracenediones. In: Chabner B.A., editor. Cancer chemotherapy and biotherapy: principles and practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins.
3. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, et al. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992.
4. Laginha KM, Verwoert S, Charrois GJ, Allen TM, (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11: 6944-6949.
5. Allen TM, Mumbengegwi DR, Charrois GJ, (2005) Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 11: 3567-3573.
6. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D, (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743.
7. Fenske DB, MacLachlan I, Cullis PR, (2001) Long-circulating vectors for the systemic delivery of genes. Curr Opin Mol Ther 3: 153-158.
8. Bally MB, Lim H, Cullis PR, Mayer LD, (1998) Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations. Journal of Liposome Research 8: 299-335.
9. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R, (1978) Design of liposomes for enhanced local release of drugs by hyperthermia. Science 202: 1290-1293.
10. Needham D, Dewhirst MW, (2001) The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 53: 285-305.
11. Li L, ten Hagen TL, Schipper D, Wijnberg TM, van Rhoon GC, et al. (2010) Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release 143: 274-279.
12. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, et al. (2000) Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 60: 6950-6957.
13. Gasselhuber A, Dreher MR, Negussie A, Wood BJ, Rattay F, et al. (2010) Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. Int J Hyperthermia 26: 499-513.
14. Poon RT, Borys N, (2009) Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 10: 333-343.
15. Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, et al. (2007) Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 13: 2722-2727.
16. Staruch R, Chopra R, Hynynen K Localised drug release using MRI-controlled focused ultrasound hyperthermia. International Journal of Hyperthermia 27: 156-171.
17. Gasselhuber A, Dreher MR, Partanen A, Yarmolenko PS, Woods D, et al. (2012) Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: Computational modelling and preliminary in vivo validation. Int J Hyperthermia 28: 337-348.
18. Hauck ML, LaRue SM, Petros WP, Poulson JM, Yu D, et al. (2006) Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 12: 4004-4010.
19. Negussie AH, Yarmolenko PS, Partanen A, Ranjan A, Jacobs G,et al. Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. Int J Hyperthermia 27: 140-155.
20. Hossann M, Wiggenhorn M, Schwerdt A, Wachholz K, Teichert N, et al. (2007) In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochim Biophys Acta 1768: 2491-2499.
21. Lindner LH, Hossann M, Vogeser M, Teichert N, Wachholz K, et al. (2008) Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release. J Control Release 125: 112-120.
22. Mills JK, Needham D, (2004) The materials engineering of temperature-sensitive liposomes. Methods Enzymol 387: 82-113.
23. El-Kareh AW, Secomb TW, (2000) A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia 2: 325-338.
24. Sinek JP, Sanga S, Zheng X, Frieboes HB, Ferrari M, et al. (2008) Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol.
25. Jackson TL, (2003) Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model. J Theor Biol 220: 201-213.
26. Zhang A, Mi X, Yang G, Xu LX, (2009) Numerical Study of Thermally Targeted Liposomal Drug Delivery in Tumor. Journal of Heat Transfer 131: 043209-043210.
27. El-Kareh AW, Secomb TW, (2005) Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. Neoplasia 7: 705-713.
28. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, et al. (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223-232.
29. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, et al. (2006) Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98: 335-344.
30. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI, (2002) Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 79: 29-40.
31. Castelli DD, Terreno E, Cabella C, Chaabane L, Lanzardo S, et al. (2009) Evidence for in vivo macrophage mediated tumor uptake of paramagnetic/fluorescent liposomes. NMR Biomed 22: 1084-1092.
32. Manzoor A (2010) Drug Delivery and Anti-vascular Effects of Temperature Sensitive Liposomal Doxorubicin. Thesis (Duke Univ).
33. Kerr DJ, Kerr AM, Freshney RI, Kaye SB, (1986) Comparative intracellular uptake of adriamycin and 4′-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survival. Biochem Pharmacol 35: 2817-2823.
34. Gigli M, Rasoanaivo TW, Millot JM, Jeannesson P, Rizzo V, et al. (1989) Correlation between growth inhibition and intranuclear doxorubicin and 4′-deoxy-4′-iododoxorubicin quantitated in living K562 cells by microspectrofluorometry. Cancer Res 49: 560-564.
35. van der Vijgh WJ, Maessen PA, Pinedo HM, (1990) Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother Pharmacol 26: 9-12.
36. Riches AC, Sharp JG, Thomas DB, Smith SV, (1973) Blood volume determination in the mouse. J Physiol 228: 279-284.
37. Yuan F, Leunig M, Berk DA, Jain RK, (1993) Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. Microvasc Res 45: 269-289.
38. Jain RK, (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039-3051.
39. Schutt DJ, Haemmerich D, (2008) Effects of variation in perfusion rates and of perfusion models in computational models of radio frequency tumor ablation. Med Phys 35: 3462-3470.
40. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, et al. (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54: 3352-3356.
41. Baxter LT, Jain RK, (1989) Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 37: 77-104.
42. Wu NZ, Klitzman B, Rosner G, Needham D, Dewhirst MW, (1993) Measurement of material extravasation in microvascular networks using fluorescence video-microscopy. Microvasc Res 46: 231-253.
43. Andresen TL, Jensen SS, Jorgensen K, (2005) Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44: 68-97.
44. Gustafson DL, Rastatter JC, Colombo T, Long ME, (2002) Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 91: 1488-1501.
45. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, et al. (1993) Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 53: 3765-3770.
46. Gabizon A, (1997) Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Advanced Drug Delivery Reviews 24: 337-344.
47. Brouckaert P, Takahashi N, van Tiel ST, Hostens J, Eggermont AM, et al. (2004) Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer 109: 442-448.
48. Patel PR, Luk A, Durrani A, Dromi S, Cuesta J, et al. (2008) In vitro and in vivo evaluations of increased effective beam width for heat deposition using a split focus high intensity ultrasound (HIFU) transducer. Int J Hyperthermia 24: 537-549.